Agree, if the MPS data is very good then no reason for a deal (even conservative) not to be on the table.
I think even with a confirmation of the 2mg and MPS results, there will be a cloud regarding funding and Management and Governance.
I get the impression from the last 2 quarters they have little handle on the spend for the trials.
I wonder whether there is a different strategy around capital conservation going forward with OA - might mean focusing on approval through TGA and a partnering there to gather funding for the phase 3 which might be delayed a bit but might also attract a partner based on Australian market success?
Anyway, a good CEO on buckets of money should be able to work through this. My near term catalyst for higher SP is appoint a Chairman and PR to signal stepping aside for a new CEO.
Agree, if the MPS data is very good then no reason for a deal...
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |